BMO Capital analyst Simeon Siegel maintained a Buy rating on TJX Companies (TJX – Research Report) today and set a price target of $75.00. The company’s shares opened today at $67.35.
According to TipRanks, Siegel is a 4-star analyst with an average return of 7.7% and a 55.86% success rate. Siegel covers the Consumer Goods sector, focusing on stocks such as Bath & Body Works, TJX Companies, and Lululemon Athletica.
TJX Companies has an analyst consensus of Strong Buy, with a price target consensus of $75.62, which is a 12.28% upside from current levels. In a report released today, Morgan Stanley also maintained a Buy rating on the stock with a $77.00 price target.
See today’s best-performing stocks on TipRanks >>
TJX market cap is currently $80.3B and has a P/E ratio of 24.45.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TJX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
The TJX Companies, Inc. is a leading off-price retailer of apparel and home fashion products. It operates T.J. Maxx and Marshalls (Marmaxx), HomeGoods, Sierra, and Homesense, as well as tjmaxx.com, marshalls.com, and sierra.com, in the U.S.; Winners, HomeSense, and Marshalls (TJX Canada) in Canada; and T.K. Maxx in the U.K., Ireland, Germany, Poland, Austria, the Netherlands, and Australia, as well as Homesense in the U.K. and Ireland, and tkmaxx.com in the U.K. (TJX International).
Read More on TJX:
- Creatd To Increase Ownership in Dune and WHE in All-Stock Transactions Priced Above Market
- Analysts Say These 2 Stocks Are Their ‘Top Picks’ for the Rest of 2022
- Wells Fargo Sticks to Its Sell Rating for Bed Bath & Beyond (BBBY)
- Suntex Enterprises, Inc. – We are Warriors
- Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board
